[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607137":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":33,"locations":38,"responsibleParty":50,"collaborators":11,"id":52,"slug":11,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":11,"overallStatus":70,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Otsuka Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"OPA-15406 foam","EXPERIMENTAL",null,[13],"Drug: OPA-15406",{"label":15,"type":10,"description":11,"interventionNames":16},"Vehicle",[17],"Drug: Vehicle",[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","OPA-15406","0.3% foam or 1% foam, topical, twice daily, for 8 weeks",[9],[25],"difamilast",{"type":20,"name":15,"description":27,"armGroupLabels":28,"otherNames":11},"vehicle, topical, twice daily, for 8 weeks",[15],[30],{"name":31,"affiliation":5,"role":32},"Nobuhito Sanada","STUDY_DIRECTOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":11},"Drug Information Center","CONTACT","+81-3-6361-7314",[39],{"facility":40,"status":11,"city":41,"state":11,"zip":11,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":11},"Sumire Dermatology Clinic","Tokyo","Japan","JP",{"type":45,"coordinates":46},"Point",[47,48],139.69171,35.6895,{"lat":48,"lon":47},{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100607137",false,"NCT07184645","A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis","A Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 0.3% OPA-15406 Foam to the Vehicle in Children With Atopic Dermatitis in Combination With an Open-label, Uncontrolled Trial to Evaluate the Safety and Efficacy of 0.3% and 1% OPA-15406 Foam in Infants Under 2 Years of Age and Children With Atopic Dermatitis (Phase 3 Trial)","Inclusion Criteria:\n\n* Participants who have been diagnosed with AD based on the Diagnostic Criteria for Atopic Dermatitis (Criteria of the Japanese Dermatological Association)\n* Participants who have an affected area covering from 5% to 40% of their body surface area (excluding the scalp) at the screening and baseline examinations\n* Participants with an IGA score of 2 or 3 at the screening and baseline examinations\n\nExclusion Criteria:\n\n* Participants who experienced an acute exacerbation of AD or contact dermatitis within 28 days prior to the baseline examination\n* Participants who have been treated with OPA-15406 ointment in the past","ALL","3 Months","14 Years",{"count":62,"type":63},198,"ESTIMATED","INTERVENTIONAL",[66],"PHASE3","To investigate the superiority of 0.3% OPA-15406 foam to the vehicle in children with atopic dermatitis (AD)",[69],"Atopic Dermatitis (AD)","NOT_YET_RECRUITING","2025-09-18",{"date":73,"type":74},"2025-09-22","ACTUAL",{"date":76,"type":63},"2025-09",{"date":78,"type":63},"2027-02",{"name":5,"class":6},1]